Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group (Q71697221)
Jump to navigation
Jump to search
scientific article published on 01 October 1996
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group |
scientific article published on 01 October 1996 |
Statements
Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group (English)
Radlmaier A
Eickenberg HU
Fletcher MS
Fourcade RO
Reis Santos JM
van Aubel OG
1 October 1996